These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Zhu Y; Yu D; Han Y; Yan H; Chong H; Ren L; Wang J; Li T; He Y Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33036961 [TBL] [Abstract][Full Text] [Related]
5. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978 [TBL] [Abstract][Full Text] [Related]
6. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731 [TBL] [Abstract][Full Text] [Related]
7. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Cohen AA; van Doremalen N; Greaney AJ; Andersen H; Sharma A; Starr TN; Keeffe JR; Fan C; Schulz JE; Gnanapragasam PNP; Kakutani LM; West AP; Saturday G; Lee YE; Gao H; Jette CA; Lewis MG; Tan TK; Townsend AR; Bloom JD; Munster VJ; Bjorkman PJ Science; 2022 Aug; 377(6606):eabq0839. PubMed ID: 35857620 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177 [TBL] [Abstract][Full Text] [Related]
9. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847 [TBL] [Abstract][Full Text] [Related]
11. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
12. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425 [TBL] [Abstract][Full Text] [Related]
13. Broad-spectrum coronavirus neutralization induced by hetero RBD-Fc protein vaccine. Zhao C; Cai G; Jiang S; Wang X; Li C; Liu X; Qiao R; Zhao X; Cui Y; Chen Y; Li J; Liu C; Yu J; Gong J; Wang P J Med Virol; 2024 Sep; 96(9):e29917. PubMed ID: 39279390 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Saunders KO; Lee E; Parks R; Martinez DR; Li D; Chen H; Edwards RJ; Gobeil S; Barr M; Mansouri K; Alam SM; Sutherland LL; Cai F; Sanzone AM; Berry M; Manne K; Bock KW; Minai M; Nagata BM; Kapingidza AB; Azoitei M; Tse LV; Scobey TD; Spreng RL; Rountree RW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Tang J; Oguin TH; Sempowski GD; Gagne M; Douek DC; Tomai MA; Fox CB; Seder R; Wiehe K; Weissman D; Pardi N; Golding H; Khurana S; Acharya P; Andersen H; Lewis MG; Moore IN; Montefiori DC; Baric RS; Haynes BF Nature; 2021 Jun; 594(7864):553-559. PubMed ID: 33971664 [TBL] [Abstract][Full Text] [Related]
15. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples. Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896 [TBL] [Abstract][Full Text] [Related]
17. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS Science; 2021 Aug; 373(6558):991-998. PubMed ID: 34214046 [TBL] [Abstract][Full Text] [Related]
18. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446 [TBL] [Abstract][Full Text] [Related]
19. Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses. Liu C; Xu S; Zheng Y; Xie Y; Xu K; Chai Y; Luo T; Dai L; Gao GF Cell Rep; 2024 May; 43(5):114235. PubMed ID: 38748880 [TBL] [Abstract][Full Text] [Related]
20. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]